151 related articles for article (PubMed ID: 12192320)
1. Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer.
Delman KA; Zager JS; Bennett JJ; Malhotra S; Ebright MI; McAuliffe PF; Halterman MW; Federoff HJ; Fong Y
Ann Surg; 2002 Sep; 236(3):337-42; discussion 342-3. PubMed ID: 12192320
[TBL] [Abstract][Full Text] [Related]
2. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma.
Herrlinger U; Jacobs A; Quinones A; Woiciechowsky C; Sena-Esteves M; Rainov NG; Fraefel C; Breakefield XO
Hum Gene Ther; 2000 Jul; 11(10):1429-38. PubMed ID: 10910140
[TBL] [Abstract][Full Text] [Related]
3. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer.
Todryk S; McLean C; Ali S; Entwistle C; Boursnell M; Rees R; Vile R
Hum Gene Ther; 1999 Nov; 10(17):2757-68. PubMed ID: 10584922
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
[TBL] [Abstract][Full Text] [Related]
6. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.
Malhotra S; Kim T; Zager J; Bennett J; Ebright M; D'Angelica M; Fong Y
Surgery; 2007 Apr; 141(4):520-9. PubMed ID: 17383529
[TBL] [Abstract][Full Text] [Related]
7. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12.
Parney IF; Farr-Jones MA; Kane K; Chang LJ; Petruk KC
Can J Neurol Sci; 2002 Aug; 29(3):267-75. PubMed ID: 12195617
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.
Ali SA; Lynam J; McLean CS; Entwisle C; Loudon P; Rojas JM; McArdle SE; Li G; Mian S; Rees RC
J Immunol; 2002 Apr; 168(7):3512-9. PubMed ID: 11907113
[TBL] [Abstract][Full Text] [Related]
9. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
10. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
11. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.
Jarnagin WR; Zager JS; Klimstra D; Delman KA; Malhotra S; Ebright M; Little S; DeRubertis B; Stanziale SF; Hezel M; Federoff H; Fong Y
Cancer Gene Ther; 2003 Mar; 10(3):215-23. PubMed ID: 12637943
[TBL] [Abstract][Full Text] [Related]
13. MCA106 fibrosarcoma cells transduced with granulocyte/macrophage colony-stimulating factor are not superior to the wild-type cells in suppressing the growth of hepatic metastases.
Dong XD; Abdel-Wahab Z; Dematos P; Fong T; Pruitt SK; Seigler HF
J Surg Oncol; 1999 May; 71(1):36-45. PubMed ID: 10362090
[TBL] [Abstract][Full Text] [Related]
14. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
Kim SH; Carew JF; Kooby DA; Shields J; Entwisle C; Patel S; Shah JP; Fong Y
Cancer Gene Ther; 2000 Sep; 7(9):1279-85. PubMed ID: 11023201
[TBL] [Abstract][Full Text] [Related]
15. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model.
Inoue H; Iga M; Xin M; Asahi S; Nakamura T; Kurita R; Nakayama M; Nakazaki Y; Takayama K; Nakanishi Y; Tani K
Cancer Immunol Immunother; 2008 Sep; 57(9):1399-411. PubMed ID: 18286286
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model.
Dunussi-Joannopoulos K; Weinstein HJ; Arceci RJ; Croop JM
J Pediatr Hematol Oncol; 1997; 19(6):536-40. PubMed ID: 9407942
[TBL] [Abstract][Full Text] [Related]
17. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection.
Janousková O; Síma P; Kunke D
Int J Oncol; 2003 Mar; 22(3):569-77. PubMed ID: 12579310
[TBL] [Abstract][Full Text] [Related]
18. Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor.
Suh KW; Piantadosi S; Yazdi HA; Pardoll DM; Brem H; Choti MA
J Surg Oncol; 1999 Dec; 72(4):218-24. PubMed ID: 10589037
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.
Nigam A; Yacavone RF; Zahurak ML; Johns CM; Pardoll DM; Piantadosi S; Levitsky HI; Nelson WG
Int J Oncol; 1998 Jan; 12(1):161-70. PubMed ID: 9454900
[TBL] [Abstract][Full Text] [Related]
20. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
